Quest Diagnostics Incorporated (DGX): Price and Financial Metrics


Quest Diagnostics Incorporated (DGX): $139.96

1.58 (+1.14%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

DGX POWR Grades


  • DGX scores best on the Quality dimension, with a Quality rank ahead of 93.12% of US stocks.
  • The strongest trend for DGX is in Sentiment, which has been heading down over the past 31 weeks.
  • DGX ranks lowest in Sentiment; there it ranks in the 9th percentile.

DGX Stock Summary

  • With a price/earnings ratio of 7.58, Quest Diagnostics Inc P/E ratio is greater than that of about merely 10.93% of stocks in our set with positive earnings.
  • Over the past twelve months, DGX has reported earnings growth of 170.68%, putting it ahead of 89.7% of US stocks in our set.
  • In terms of volatility of its share price, DGX is more volatile than just 1.64% of stocks we're observing.
  • Stocks that are quantitatively similar to DGX, based on their financial statements, market capitalization, and price volatility, are AEM, FOXA, FBHS, PKI, and PHM.
  • Visit DGX's SEC page to see the company's official filings. To visit the company's web site, go to www.questdiagnostics.com.

DGX Valuation Summary

  • In comparison to the median Healthcare stock, DGX's price/sales ratio is 58.33% lower, now standing at 1.5.
  • Over the past 243 months, DGX's price/sales ratio has gone down 0.4.
  • Over the past 243 months, DGX's price/sales ratio has gone down 0.4.

Below are key valuation metrics over time for DGX.

Stock Date P/S P/B P/E EV/EBIT
DGX 2019-04-15 1.6 2.3 16.6 14.7
DGX 2018-10-19 1.8 2.7 17.3 15.5
DGX 2016-03-18 1.3 2.1 14.1 11.0
DGX 2014-09-15 1.3 2.2 11.5 9.0
DGX 2002-08-09 1.5 3.9 29.2 15.1
DGX 2002-07-29 1.5 3.8 28.5 14.8

DGX Growth Metrics

  • The year over year revenue growth rate now stands at 34.97%.
  • The 4 year revenue growth rate now stands at 1.86%.
  • Its year over year cash and equivalents growth rate is now at 259.65%.
DGX's revenue has moved up $2,707,000,000 over the prior 30 months.

The table below shows DGX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 10,335 2,489 1,801
2020-12-31 9,437 2,005 1,431
2020-09-30 8,361 1,812 1,105
2020-06-30 7,531 1,249 752
2020-03-31 7,657 1,215 793
2019-12-31 7,726 1,243 858

DGX Price Target

For more insight on analysts targets of DGX, see our DGX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $145.21 Average Broker Recommendation 1.53 (Moderate Buy)

DGX Stock Price Chart Interactive Chart >

Price chart for DGX

DGX Price/Volume Stats

Current price $139.96 52-week high $142.80
Prev. close $138.38 52-week low $104.10
Day low $138.06 Volume 1,153,900
Day high $140.17 Avg. volume 1,241,507
50-day MA $131.81 Dividend yield 1.79%
200-day MA $126.59 Market Cap 18.28B

Quest Diagnostics Incorporated (DGX) Company Bio


Quest Diagnostics provides diagnostic testing information services in the United States and internationally. The company offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, as well as related services and insights; laboratory testing services for new drugs, vaccines, and medical devices, analytic, on-site prevention, and wellness services, and risk assessment services for the life insurance industry. The company was founded in 1967 and is founded in Madison, New Jersey.

DGX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$139.96$337.75 157%

Below please find a table outlining a discounted cash flow forecast for DGX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Quest Diagnostics Inc ranked in the 74th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 158.5% on a DCF basis. In terms of the factors that were most noteworthy in this DCF analysis for DGX, they are:

  • The company has produced more trailing twelve month cash flow than 83.97% of its sector Healthcare.
  • Quest Diagnostics Inc's weighted average cost of capital (WACC) is 9%; for context, that number is higher than only 15.51% of tickers in our DCF set.
  • DGX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than only 15.51% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%152%
1%155%
2%157%
3%160%
4%162%
5%165%

Want more companies with a valuation profile/forecast similar to that of Quest Diagnostics Inc? See ANIP, SELB, COLL, HNGR, and TVTY.


DGX Latest News Stream


Event/Time News Detail
Loading, please wait...

DGX Latest Social Stream


Loading social stream, please wait...

View Full DGX Social Stream

Latest DGX News From Around the Web

Below are the latest news stories about Quest Diagnostics Inc that investors may wish to consider to help them evaluate DGX as an investment opportunity.

Revenue Cycle Management (RCM) Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:Athenahealth, Cerner Corporation, Eclinicalworks, Mckesson, Quest Diagnostics, Al

This report studies the Revenue Cycle Management (RCM) Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Revenue Cycle Management (RCM) market segmented []

Jumbo News | July 24, 2021

Women Health Diagnostics Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:Quest Diagnostics, Abbott, BD, Roche, GE Healthcare, Biomérieux, Philips, DIALAB, Fuji

This report studies the Women Health Diagnostics Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Women Health Diagnostics market segmented by company, []

Jumbo News | July 24, 2021

Cervical Cancer Screening Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:Abbott Laboratories, Hologic, Qiagen, Hoffmann-La Roche, Quest Diagnostics, Becton, Di

This report studies the Cervical Cancer Screening Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Cervical Cancer Screening market segmented by company, []

Jumbo News | July 24, 2021

How Many Quest Diagnostics Incorporated (NYSE:DGX) Shares Do Institutions Own?

If you want to know who really controls Quest Diagnostics Incorporated ( NYSE:DGX ), then you'll have to look at the...

Yahoo | July 24, 2021

Global C-Reactive Protein (CRP) Test Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: HORIBA, Thermo Fisher Scientific, F Hoffmann-La Roche, Quest Diagnostics, Abbott, Siemens Healthineers, Danaher, Ortho Clinical Diagnostics, Orion Diagnostica, Merck, Abaxis, BODITECH MED, Getein Biotech, Randox Laboratories

The report on Global C-Reactive Protein (CRP) Test Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a []

Jumbo News | July 23, 2021

Read More 'DGX' Stories Here

DGX Price Returns

1-mo 6.80%
3-mo 6.96%
6-mo 9.40%
1-year 15.53%
3-year 39.71%
5-year 79.21%
YTD 19.10%
2020 14.11%
2019 31.13%
2018 -13.84%
2017 9.16%
2016 31.90%

DGX Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full DGX Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8865 seconds.